A Clinical Study to Map the HLA Genomic Region in the Greek Population

Официальное название

A Clinical Study to Map the HLA GENomic Region and Its potEntial aSsocIation With Selected diSeases in the Greek Population

Обзор

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

Подробное описание

The GENESIS study is a multicenter, prospective, non-interventional, clinical study with a target of 12,000 subjects and an anticipated total duration of 36 months. The aim of study GENESIS is to provide a pilot map of HLA genetic variation in the Greek population in order to be used in medical research and for possible clinical applications (evaluation of possible correlations with selected underlying diseases). During the study, each subject will conduct one visit to the participating cite, in which they will provide:

1. Demographic information \[i.e. date of birth, gender, race, ancestry (including information about the subject's grandparents' birthplace), height, weight\], 2. Other information about smoking/vaping, alcohol consumption, arterial blood pressure, diagnosed diseases (if any), current treatments (if any), and 3. Recent (up to 12 months prior to sample collection) results if/when are available from clinical lab tests such as blood count (Hct, Hb, RBC, WBC, PLT count), including a metabolic panel, liver enzymes and biochemical parameters (Glu, HbA1c, TC, TG, LDL-C, HDL-C, ALT, AST, ALP, γGT, bilirubin, LDH, insulin, C-peptide).

Upon completion of the data registry, two buccal swabs will be collected per subject and they will be stored at ALTP premises until their shipment to Galatea.Bio. All buccal swab samples will be subjected to genetic material (DNA) extraction. The DNA samples will be further proceeded for HLA genotyping analysis. A follow up analysis will be performed in selected DNA samples via full low-pass whole genome sequencing (LP-WGS), which aims to further investigate the association between the HLA region and autoimmune diseases.

Upon completion of the analysis, an individualized ancestry report will be securely made available to all study subjects which they can access, as and if they elect to.

Первичные конечные точки

• Allele frequency of HLA-alleles at the Greek population level [Срок оценки: 36th month]

Вторичные конечные точки (2)

• Prevalence of selected HLA-related diseases in the Greek population [Срок оценки: 36th month]
• Relative Risk (Risk Ratio (RR) or Odds Ratio (OR)) of HLA markers on diseases of interest [Срок оценки: 36th month]

Критерии участия

Критерии включения

The study will include adult subjects (age ≥ 18) that:

• possess a Greek social security number and are visiting hospitals/clinics, and/or other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,
• are willing and able to provide written informed consent to participate in the study according to the study protocol.

Критерии исключения

• Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).
• Subjects who have had an allogeneic (non-self-donor):

• bone marrow transplant
• stem cell transplant
• blood transfusion less than two weeks prior to buccal swab sample collection
• liver transplant
• Subjects who participated in an interventional clinical trial in the past that according to the subject's physician opinion might have had an impact on their HLA genome.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения

Другое

Центры проведения

Греция · 8 центров

• 2nd Propaedeutic Department of Internal Medicine, Attikon University General Hospital — Chaïdári
• 2nd Department of Neurology, AHEPA University Hospital — Thessaloniki
• Department of Respiratory Medicine, University General Hospital of Alexandroupolis — Alexandroupoli
• Department of Infectious Diseases, 2nd Department of Internal Medicine, University General — Alexandroupoli
• Department of Cardiology, University General Hospital of Heraklion — Heraklion
• Department of Rheumatology, University Hospital of Heraklion — Heraklion
• Department of Respiratory, University Hospital of Ioannina — Ioannina
• Department of Haematology, University General Hospital of Larissa — Larissa

Публикации

• Sanchez-Mazas A, Nunes JM, Middleton D, Sauter J, Buhler S, McCabe A, Hofmann J, Baier DM, Schmidt AH, Nicoloso G, Andreani M, Grubic Z, Tiercy JM, Fleischhauer K. Common and well-documented HLA alleles over all of Europe and within European sub-regions: A catalogue from the European Federation for Immunogenetics. HLA. 2017 Feb;89(2):104-113. doi: 10.1111/tan.12956. PMID 28102034
• Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018 May;18(5):325-339. doi: 10.1038/nri.2017.143. Epub 2018 Jan 2. PMID 29292391
• Zhou Y, Krebs K, Milani L, Lauschke VM. Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing. Clin Pharmacol Ther. 2021 Jan;109(1):160-174. doi: 10.1002/cpt.1944. Epub 2020 Jul 26. PMID 32535895

Идентификаторы

NCT: NCT06227468 · ALTP.2023.001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗